DUBLIN, IRELAND, September 8, 2026 /EINPresswire.com/ — Ensera, a global leader in contract design, contract manufacturing, and packaging services for the pharmaceutical and medical device industries, today announced a strategic alliance with American Injectables, a Florida-based CDMO specializing in the fill-finish of sterile injectable drugs. The partnership aims to offer pharma companies, seeking a fast and flexible route into the North American market, a seamless bridge from aseptic fill-finish to final device assembly, secondary packaging, and serialization.
Both companies operate state-of-the-art manufacturing facilities located just miles apart in Central Florida, purpose-built to support small- to medium-scale production with speed and precision. Their combined capabilities deliver a single, integrated, end-to-end solution for critical injectable drug therapies, underpinned by a shared culture of agility, accountability, and quality-first thinking.
“This alliance reflects a strong alignment not only in technical capabilities but also in mindset,” said Bobby O’Connor, Chief Commercial Officer at Ensera. “American Injectables’ facility, team, and approach are a perfect complement to Ensera’s expanding pharmaceutical manufacturing operations in Florida. Together, we are enabling pharma innovators to bring critical therapies to market with confidence, speed, and scalability.”
Ensera, formerly SteriPack, completed a significant upgrade to its Florida site in April 2025, expanding its pharmaceutical services for drug device manufacturing, final assembly, and secondary packaging of combination products. American Injectables recently completed a major expansion of its FDA-registered and inspected manufacturing facility, with additional filling capacity.
“We’ve built American Injectables with a relentless focus on quality, speed, and service,” said Travis Allen, Chief Executive Officer and Board Director, at American Injectables. “Our alliance with Ensera expands that vision across the entire supply chain, delivering a one-stop-shop for companies developing sterile injectable and combination products.”
This announcement is particularly timely as more pharmaceutical companies look to regionalize supply chains and increase resilience in the delivery of essential medicines. With both facilities located in Florida, the alliance offers a strategic geographic advantage for companies targeting the U.S. market.
The partnership is the latest industry alliance confirmed by Ensera. It follows the recent partnership announcement with fill-finish CDMO Argonaut as well as established assembly partnerships with platform device companies Ypsomed, SHL Medical, and BD, intended to ensure fewer handovers, clearer accountability and smoother progression from development through commercialization.
About Ensera
Ensera offers contract design and manufacturing services to the pharmaceutical and medical device industries, specializing in drug delivery and combination product solutions. With dedicated design and manufacturing facilities across North America, Europe, and Southeast Asia, Ensera delivers flexible, scalable, and regulatory-compliant support from concept to commercial launch.
About American Injectables
American Injectables is a privately held, U.S.-based CDMO specializing in sterile injectable drug products. Its FDA-registered and inspected, state-of-the-art facility in Florida is purpose-built for agility, quality, and scalability, supporting partners from formulation through clinical and commercial manufacturing. The company delivers flexible, end-to-end solutions for vials, syringes, and cartridges, serving both U.S. and global markets.
Media Contacts
Ensera – Josh Lowth, j.lowth@ensera.com
American Injectables – Jennifer Kline, jennifer.kline@americaninj.com
Josh Lowth
Ensera
email us here
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
